Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in COVID-19 inflammatory stage
NCT04941105Phase 3Completed
- Sponsor
- Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz. Primary endpoint: Death from any cause or need for intubation at 30 days. Started Jun 2021; status: completed.
02
Drugs
evolocumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04941105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941105.